Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Core Points - Genmab A/S announced plans to offer $1.5 billion of senior secured notes due 2032 and $1.0 billion of senior unsecured notes due 2033, alongside a new $2.0 billion senior secured term loan "B" facility [1] - The financing is part of the acquisition of Merus N.V., which includes previously syndicated credit facilities totaling $1.5 billion [1] - A preliminary offering memorandum has been provided to potential investors, containing undisclosed information and pro forma financial data related to the acquisition [2] Financial Information - The preliminary offering memorandum includes unaudited pro forma condensed combined financial information for the nine months ended September 30, 2025, and for the year ended December 31, 2024 [2] - Audited consolidated financial statements for the years ended December 31, 2024, 2023, and 2022 are also included, originally prepared in Danish Kroner and retranslated into US Dollars [2]